Researchers see promise in generic/4032 combo for melanoma; Biosimilars market to hit $3.7B in 2015;

@FierceBiotech: Which are the best dealmakers in the biopharma business? Item | Follow @FierceBiotech

@JohnCFierce: Tiny San Diego-based Novalar says that it will shut down now that it has sold its only product. Report | Follow @JohnCFierce

> Researchers say that animal studies indicate that the generic arthritis drug leflunomide could be effective against melanoma, especially if it's combined with Plexxikon's closely watched PLX-4032. Story

> Champions Biotechnology has agreed to put its personalized cancer tech to work on two of Cephalon's compounds, snagging a $1.4 million payout and the promise of up to $27 million more. Report

> AstraZeneca's Brilinta, a challenger for the Plavix market, has hit a fresh roadblock in France, where reimbursement regulators are asking for more information. Story

> Israel's Protalix is hatching plans to launch two new clinical programs for drugs that treat Fabry disease and rheumatoid arthritis. The biotech is shooting for new approvals in 2016.  Report

> Some analysts say it's time for a cash-rich Amgen to pay its first dividend. Story

Pharma News

@FiercePharma:  With Sanofi-Merck deal off, look for animal health M&A. Item | Follow @FiercePharma

> Does Steere's exit signal a new day at Pfizer? News

> Judge tosses ex-GSK lawyer's indictment on legal snafu. Article

> FDA lifts fracture warning on OTC stomach meds. Story

> More supply woes as Genzyme scraps Fabrazyme batch. Report

> Bristol chief nabs $10.9M pay package for 2010. News

Vaccines News

> Skipped MMR vaccines lead to oubreak in Minnesota. Item

> Promising protein may yield TB vax. News

> Inovio gets DNA vaccine grant from DoD. Report 

> Novartis gains majority ownership of Zhejiang Tianyuan. Story

Manufacturing News

> FDA steps up counterfeit drug investigations. Story

> KV blinks, but Makena pricing tactic common. Item 

> India sets tone for drug production in Nigeria. Article

> Science uses art tool to ID drug colors. Report

> Fabrazyme falls victim to fill/finish. Story 

> UK pushes continuous manufacturing. News 

And Finally... Datamonitor says that the market for biosimilar drugs will skyrocket from $243 million in 2010 to $3.7 billion by 2015. Story

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.